UCM-13207

• Description :

  UCM-13207 (compound 21) is a selective ICMT inhibitor that ameliorates basic progeria-like features. UCM-13207 can improve the survival rate of LmnaG609G/G609G mice in the mouse premature aging model[1].

• UNSPSC :

  12352005

• Target :

  ICMT

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/ucm-13207.html

• Purity :

  99.61

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(CCN(CCCCCCCC)C(C1=CC=CC=C1)=O)NC2=CC=CC=C2

• Molecular Formula :

  C24H32N2O2

• Molecular Weight :

  380.52

• References & Citations :

  [1]Marcos-Ramiro B et al. Isoprenylcysteine carboxylmethyltransferase-based therapy for Hutchinson–Gilford progeria syndrome[J]. ACS Central Science, 2021, 7 (8) : 1300-1310.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1621536-10-4]